Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-28T00:58:09.715Z Has data issue: false hasContentIssue false
  • English
  • Français

Serum levels of interleukins 4 and 10 in head and neck squamous cell carcinoma

Published online by Cambridge University Press:  05 September 2011

Z Mojtahedi ,
B Khademi ,
A Yehya ,
A Talebi ,
M J Fattahi  and
A Ghaderi
Z Mojtahedi
Affiliation:
Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran
B Khademi
Affiliation:
Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran
A Yehya
Affiliation:
Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran
A Talebi
Affiliation:
Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran
M J Fattahi
Affiliation:
Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran
A Ghaderi*
Affiliation:
Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran
*
Address for correspondence: Abbas Ghaderi, Professor of Immunology, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran Fax: 0098 711 2304952 E-mail: ghaderia@sums.ac.ir
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

There is currently controversy over the association between serum interleukin-4 and -10 levels and head and neck squamous cell carcinoma in patients of different ethnicity. This study aimed to investigate serum levels of these cytokines in Iranian patients with this pathology, and to analyse correlations with tumour location and tumour stage at diagnosis.

Design:

Serum cytokines levels were quantified using commercial enzyme-linked immunosorbent assays.

Subjects:

Study groups comprised 93 untreated patients and 53 healthy donors.

Results:

Serum interleukin-4 levels were significantly increased in patients compared with controls (p < 0.000), but were not significantly associated with tumour stage. Serum interleukin-10 levels were not raised in patients, nor associated with tumour stage.

Conclusion:

Serum levels of interleukin-4, but not -10, were increased in Iranian head and neck squamous cell carcinoma patients. These data do not support an association of these cytokines with tumour progression; this is consistent with previous findings.

Keywords

CarcinomaSquamous CellInterleukin-4Interleukin-10Head And Neck NeoplasmsImmunosuppression
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 126 , Issue 2 , February 2012 , pp. 175 - 179
Copyright
Copyright © JLO (1984) Limited 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Hardisson, D. Molecular pathogenesis of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2003;260:502–8CrossRefGoogle ScholarPubMed
2Li, Z, Chen, L, Qin, Z. Paradoxical roles of IL-4 in tumor immunity. Cell Mol Immunol 2009;6:415–22CrossRefGoogle ScholarPubMed
3Salazar-Onfray, F, López, MN, Mendoza-Naranjo, A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 2007;18:171–82CrossRefGoogle ScholarPubMed
4Samsami Dehaghani, A, Shahriary, K, Kashef, MA, Naeimi, S, Fattahi, MJ, Mojtahedi, Z et al. Interleukin-18 gene promoter and serum level in women with ovarian cancer. Mol Biol Rep 2009;36:2393–7CrossRefGoogle ScholarPubMed
5Jebreel, A, Mistry, D, Loke, D, Dunn, G, Hough, V, Oliver, K et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol 2007;121:246–52CrossRefGoogle ScholarPubMed
6Yamamoto, T, Yoneda, K, Ueta, E, Osaki, T. Serum cytokines, interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in oral disorders. Oral Surg Oral Med Oral Pathol 1994;78:727–35CrossRefGoogle ScholarPubMed
7Karcher, J, Reisser, C, Daniel, V, Herold-Mende, C. Cytokine expression of transforming growth factor-beta2 and interleukin-10 in squamous cell carcinomas of the head and neck. Comparison of tissue expression and serum levels [in German]. HNO 1999;47:879–84CrossRefGoogle ScholarPubMed
8Lathers, DM, Young, MR. Increased aberrance of cytokine expression in plasma of patients with more advanced squamous cell carcinoma of the head and neck. Cytokine 2004;25:220–8CrossRefGoogle ScholarPubMed
9Lathers, DM, Achille, NJ, Young, MR. Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum Immunol 2003;64:1160–6CrossRefGoogle ScholarPubMed
10Hoffmann, TK, Sonkoly, E, Homey, B, Scheckenbach, K, Gwosdz, C, Bas, M et al. Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck. Head Neck 2007;29:472–8CrossRefGoogle ScholarPubMed
11Prokopchuk, O, Liu, Y, Henne-Bruns, D, Kornmann, M. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Br J Cancer 2005;92:921–8CrossRefGoogle ScholarPubMed
12Mojtahedi, Z, Khademi, B, Hashemi, SB, Abtahi, SMB, Ghasemi, MA, Fattahi, MJ et al. Serum interleukine-6 concentration, but not interleukine-18, is associated with head and neck squamous cell carcinoma progression. Pathol Oncol Res 2011;17:7–10CrossRefGoogle Scholar
13Duffy, SA, Taylor, JM, Terrell, JE, Islam, M, Li, Y, Fowler, KE et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008;113:750–7CrossRefGoogle ScholarPubMed
14Fauci, AS, Braunwald, E, Kasper, DL, Hauser, SL, Longo, DL, Jameson, JL. Harrison's principles of internal medicine. In: Vokes, EE. Head and Neck Cancer, 17th edn.New York: McGraw-Hill, 2008;549–50Google Scholar
15Satyam, A, Singh, P, Badjatia, N, Seth, A, Sharma, A. A disproportion of T(H)1/T(H)2 cytokines with predominance of T(H)2, in urothelial carcinoma of bladder. Urol Oncol 2011;29:58–65CrossRefGoogle Scholar